This site uses cookies. By continuing to browse the site, you are agreeing to our use of cookies.

The LIBERATE trial, recently published on the American Journal of Respiratory and Clinical Care Medicine, demonstrated that treating severe emphysema with endobronchial valves (EBVs) improves lung function, exercise tolerance and quality of life a year after treatment. The EBVs approach resulted in a less invasive method with minimally complications compared to lung volume reduction surgery (LVRS).